Af­ter a brief break, As­traZeneca is back at di­vest­ing — hand­ing off hy­per­ten­sion meds for $350M

On the same day that it’s get­ting back an ex­per­i­men­tal IL-23 drug from Ab­b­Vie and Al­ler­gan’s pre-merg­er di­vesti­ture ex­er­cise, As­traZeneca has en­gi­neered a sale of its own.

The phar­ma gi­ant is col­lect­ing $350 mil­lion from At­nahs Phar­ma for glob­al com­mer­cial rights to a suite of five off-patent hy­per­ten­sion drugs: In­der­al (pro­pra­nolol), Tenormin (atenolol), Tenoret­ic (atenolol, chlorthali­done fixed-dose com­bi­na­tion), Zestril (lisino­pril) and Ze­storet­ic (lisino­pril, hy­drochloroth­iazide fixed-dose com­bi­na­tion).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER